AIM
XENE icon

Acrospire Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Acrospire Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-61
Closed – – 2574
2017
Q1 		$0 Buy
+61
New +$480 ﹤0.01% 2531

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acrospire Investment Management's XENE Position: Q2 2017 in Review

Acrospire Investment Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2017, closing a stake of 61 shares.

Acrospire Investment Management first reported a position in XENE in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 39 funds tracked by Wall St. Rank hold XENE as of Q2 2017.

  • Acrospire Investment Management reported no remaining Xenon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 61 Xenon Pharmaceuticals shares in Q2 2017.
  • Acrospire Investment Management first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Xenon Pharmaceuticals position peaked at $0 in Q1 2017.
  • 39 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.